EMA OKs BMS/bluebird bio’s CAR-T Abecma For Multiple Myeloma

Other EU Recommendations Include Astellas’s Roxadustat & BioMarin’s Vosoritide

 
• By Ian Schofield

A gene therapy for multiple myeloma, a new drug for achondroplasia, and the first biosimilar version of Roche’s Lucentis are among eight products recommended for EU marketing authorization this week.

Gene editing genes therapy concept with nurse and DNA lab technician medical laboratory
A gene therapy for multiple myeloma could soon be approved in Europe • Source: Shutterstock

More from Approvals

More from Product Reviews